Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice

Lipid metabolism disorders contribute to hyperlipidemia and hepatic steatosis. It is ideal to develop drugs simultaneous improving both hyperlipidemia and hepatic steatosis. Nitazoxanide is an FDA-approved oral antiprotozoal drug with excellent pharmacokinetic and safety profile. We found that nitaz...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fengfeng, Jiang, Man, Ma, Minghui, Chen, Xuyang, Zhang, Yidan, Zhang, Yixin, Yu, Yuanyuan, Cui, Yunfeng, Chen, Jiahui, Zhao, Hui, Sun, Zhijie, Dong, Deli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069401/
https://www.ncbi.nlm.nih.gov/pubmed/35530137
http://dx.doi.org/10.1016/j.apsb.2021.09.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069401/
https://www.ncbi.nlm.nih.gov/pubmed/35530137
http://dx.doi.org/10.1016/j.apsb.2021.09.009

Ejemplares similares